Formato Vancouver:
Fernández Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M et al. PRONEDI Study Group. Effect of dual blockade of the renin-angiotensin system on the progression
of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis. 2013 Feb;61(2):211-8.

PMID: 22939518

Contiene 28 referencias

Background: Blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has been shown to lessen the rate of decrease in glomerular filtration rate in patients with diabetic nephropathy. Study Design: A multicenter open-label randomized controlled trial to compare the efficacy of combining the angiotensin-converting enzyme inhibitor lisinopril and the angiotensin II receptor blocker irbesartan with that of each drug in monotherapy (at both high and equipotent doses) in slowing the progression of type 2 diabetic nephropathy. Setting & Population: 133 patients with type 2 diabetic nephropathy (age, 66 +/- 8 years; 76% men) from 17 centers in Spain. Intervention: Patients were randomly assigned (1:1:2) to lisinopril (n = 35), irbesartan (n = 28), or the combination of both (n = 70). Outcomes: The primary composite outcome was a >50% increase in baseline serum creatinine level, end-stage renal disease, or death. Results: Baseline values for mean estimated glomerular filtration rate and blood pressure were 49 +/- 21 mL/min/1.73 m(2) and 153 +/- 19/81 +/-